Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Abdollah, F; Sammon, JD; Reznor, G; Sood, A; Schmid, M; Klett, DE; Sun, M; Aizer, AA; Choueiri, TK; Hu, JC; Kim, SP; Kibel, AS; Nguyen, PL; Menon, M; Trinh, QD.
Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years.
Eur J Surg Oncol. 2015; 41(11):1529-39
Doi: 10.1016/j.ejso.2015.06.011
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Leitsmann Marianne
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: To examine the potential relationship between androgen deprivation therapy and other-cause mortality (OCM) in patients with prostate cancer treated with medical primary-androgen deprivation therapy, prostatectomy, or radiation. METHODS: A total of 137,524 patients with non-metastatic PCa treated between 1995 and 2009 within the Surveillance Epidemiology and End Results Medicare-linked database were included. Cox-regression analysis tested the association of ADT with OCM. A 40-item comorbidity score was used for adjustment. RESULTS: Overall, 9.3% of patients harbored stage III-IV disease, and 57.7% of patients received ADT. The mean duration of ADT exposure was 22.9 months (median: 9.1; IQR: 2.8-31.5). Mean and median follow-up were 66.9, and 60.4 months, respectively. At 10 years, overall-OCM rate was 36.5%; it was 30.6% in patients treated without ADT vs. 40.1% in patients treated with ADT (p < 0.001). In multivariable-analysis, ADT was associated with an increased risk of OCM (Hazard-ratio [HR]: 1.11, 95% Confidence-interval [95% CI]: 1.08-1.13). Patients with no comorbidity (10-year OCM excess risk: 9%) were more subject to harm from ADT than patients with high comorbidity (10-year OCM excess risk: 4.7%). CONCLUSIONS: In patients with PCa, treatment with medical ADT may increase the risk of mortality due to causes other than PCa. Whether this is a simple association or a cause-effect relationship is unknown and warrants further study in prospective studies.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Aged, 80 and over - administration & dosage
- Androgen Antagonists - therapeutic use
- Antineoplastic Agents, Hormonal - therapeutic use
- Cardiovascular Diseases - complications, mortality
- Cause of Death - trends
- Follow-Up Studies - administration & dosage
- Humans - administration & dosage
- Male - administration & dosage
- Prospective Studies - administration & dosage
- Prostatectomy - methods
- Prostatic Neoplasms - complications, therapy
- Registries - administration & dosage
- Risk Assessment - methods
- Risk Factors - administration & dosage
- SEER Program - administration & dosage
- Survival Rate - trends
- United States - epidemiology
- Find related publications in this database (Keywords)
- Prostate cancer
- Androgen deprivation therapy
- Comorbidity
- Other-cause mortality
- Competing-risks